Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer

Journal of Clinical Oncology

Volumn 17, Issue 5, 1999, Pages 1474-1481

  Harvey, Jennet M ^a   Clark, Gary M ^a   Osborne, C Kent ^a   Allred, D Craig ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; TAMOXIFEN;

ARTICLE; BREAST CANCER; CANCER CYTODIAGNOSIS; CANCER HORMONE THERAPY; DRUG RESPONSE; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LIGAND BINDING; LONG TERM CARE; PRIORITY JOURNAL; PROGNOSIS; RECEPTOR DENSITY; TISSUE SECTION; TREATMENT OUTCOME;

EID: 0032896905     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.5.1474     Document Type: Article

References (57)

1. McGuire WL: Breast cancer prognostic factors: Evaluation guidelines. J Natl Cancer Inst 83:154-155, 1991 (editorial)
2. Clark GM: Prognostic and predictive factors, in Harris J, Lippman ME, Morrow M, et al (eds): Diseases of the Breast. Philadelphia, PA, Lippincott-Raven, 1996, pp 461-485
3. ASCO Tumor Marker Expert Panel: Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. J Clin Oncol 14:2843-2877, 1996
4. Knight WAI, Livingston RB, Gregory EJ, et al: Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer. Cancer Res 37:4669-4671, 1977
5. Greene GL, Nolan C, Engler P, et al: Monoclonal antibodies to human estrogen receptor. Proc Natl Acad Sci U S A 77:5115-5119, 1980
6. King WJ, Greene GL: Monoclonal antibodies localize oestrogen receptor in the nuclei of target cells. Nature 307:745-747, 1984
7. Allred DC, Harvey JM, Berardo MD, et al: Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 11:155-168, 1998
8. Clark GM, Dressler LG, Owens MA, et al: Prediction of relapse or survival in patients with node-negative breast cancer by DNA flow cytometry. N Engl J Med 320:627-633, 1989
9. McGuire WL, De La Garza M, Chamness GC: Evaluation of estrogen receptor assays in human breast cancer tissue. Cancer Res 37:637-639, 1977
10. Clark GM, Osborne CK, McGuire WL: Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer. J Clin Oncol 2:1102-1109, 1984
11. Clark GM: Do we really need prognostic factors in breast cancer? Breast Cancer Res Treat 30:117-126, 1993
12. Clark GM, Wenger CR, Beardslee S, et al: How to integrate steroid hormone receptor, flow cytometric, and other prognostic information in regard to primary breast cancer. Cancer 71:2157-2162, 1993
13. Allred DC, Clark GM, Tandon AK, et al: Immunohistochemistry on histological sections from small (50 mg) samples of pulverized breast cancer. J Histotechnol 16:117-120, 1993
14. Allred DC, Clark GM, Elledge R, et al: Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 85:200-206, 1993
15. Hilsenbeck SG, Clark GM: Practical p-value adjustment for optimally selected cutpoints. Stat Med 15:103-112, 1996
16. Osborne CK: Receptors, in Harris JR, Hellman S, Henderson IC, et al (eds): Breast Diseases. Philadelphia, PA, Lippincott, 1991, pp 301-325
17. Allred DC, Bustamante MA, Daniel CO, et al: Immunocytochemical analysis of estrogen receptors in human breast carcinomas: Evaluation of 130 cases and review of the literature regarding concordance with biochemical assay and clinical relevance. Arch Surg 125:107-113, 1990
18. DeSombre ER, Thorpe SM, Rose C, et al: Prognostic usefulness of estrogen receptor immunocytochemical assays for human breast cancer. Cancer Res 46:4256S-4264S, 1986 (suppl)
19. Walker KJ, Bouzubar N, Robertson J, et al: Immunocytochemical localization of estrogen receptor in human breast tissue. Cancer Res 48:6517-6522, 1988
20. Kinsel LB, Szabo E, Greene GL, et al: Immunocytochemical analysis of estrogen receptors as a predictor of prognosis in breast cancer patients: Comparison with quantitative biochemical methods. Cancer Res 49:1052-1056, 1989
21. Pertschuk LP, Kim DS, Nayer K, et al: Immunocytochemical estrogen and progestin receptor assays in breast cancer with monoclonal antibodies: Histopathologic, demographic, and biochemical correlations and relationship to endocrine response and survival. Cancer 66:1663-1670, 1990
22. Reiner A, Neumeister B, Spona J, et al: Immunocytochemical localization of estrogen and progesterone receptor and prognosis in human primary breast cancer. Cancer Res 50:7057-7061, 1990
23. Andersen J, Thorpe SM, King WJ, et al: The prognostic value of immunohistochemical estrogen receptor analysis in paraffin-embedded and frozen sections versus that of steroid-binding assays. Eur J Cancer 26:442-449, 1990
24. Cowen PN, Teasdale J, Jackson P, et al: Oestrogen receptor in breast cancer: Prognostic studies using a new immunohistochemical assay. Histopathology 17:319-325, 1990
25. Seymour L, Meyer K, Esser J, et al: Estimation of PR and ER by immunocytochemistry in breast cancer: Comparison with radioligand binding methods. Am J Clin Pathol 94:S35-S40, 1990 (suppl 1)
26. Andersen J, Thorpe SM, Rose C, et al: Estrogen receptor in primary breast cancer estimated in paraffin-embedded tissue. Acta Oncol 30:685-690, 1991
27. Querzoli P, Ferretti S, Marzola A, et al: Clinical usefulness of estrogen receptor immunocytochemistry in human breast cancer. Tumori 78:287-290, 1992
28. Robertson JFR, Bates K, Pearson D, et al: Comparison of two oestrogen receptor assays in the prediction of the clinical course of patients with advanced breast cancer. Br J Cancer 65:727-730, 1992
29. Hurlimann J, Gebhard S, Gomez F: Oestrogen receptor, progesterone receptor, pS2, ERD5, HSP27 and cathepsin D in invasive ductal breast carcinomas. Histopathology 23:239-248, 1993
30. Hanna W, McReady DR, Chapman JW, et al: The predictive value of ERICA in breast cancer recurrence: A univariate and multivariate analysis. Mod Pathol 6:748-754, 1993
31. Battifora H, Mehta P, Esteban JM: Estrogen receptor immunohistochemical assay in paraffin-embedded tissue: A better gold standard? Appl Immunohistochem 1:39-45, 1993
32. Esteban JM, Ahn C, Mehta P, et al: Biologic significance of quantitative estrogen receptor immunohistochemical assay by image analysis in breast cancer. Am J Clin Pathol 102:158-162, 1994
33. Kommoss F, Pfisterer J, Idris T, et al: Steroid receptors in carcinoma of the breast: Results of immunocytochemical and biochemical determination and their effects on short-term prognosis. Anal Quant Cytol Histol 16:203-210, 1994
34. Beck T, Weikel W, Brumm C, et al: Immunohistochemical detection of hormone receptors in breast carcinomas (ER-ICA, PgR-ICA): Prognostic usefulness and comparison with the biochemical radioactive ligand-binding assay (DCC). Gynecol Oncol 53:220-227, 1994
35. Stierer M, Rosen H, Weber R, et al: A prospective analysis of immunohistochemically determined hormone receptors and nuclear features as predictors of early recurrence in primary breast cancer. Breast Cancer Res Treat 36:11-21, 1995
36. Ferno M, Andersson C, Fallenius G, et al: Oestrogen receptor analysis of paraffin sections and cytosol samples of primary breast cancer in relation to outcome after adjuvant tamoxifen treatment. Acta Oncol 35:17-22, 1996
37. Layfield LJ, Saria EA, Conlon DH, et al: Estrogen and progesterone receptor status determined by the Ventana ES 320 automated immunohistochemical stainer and the CAS 200 image analyzer in 236 early-stage breast carcinomas: Prognostic significance. J Surg Oncol 61:177-184, 1996
38. Ferrer-Roca OF, Ramos A, Diaz-Cardama A: Immunohistochemical correlation of steroid receptors and disease-free interval in 206 consecutive cases of breast cancer: Validation of telequantification based on global scene segmentation. Anal Cell Pathol 9:151-163, 1995
39. Molino A, Micciolo R, Turazza M, et al: Prognostic significance of estrogen receptors in 405 primary breast cancers: A comparison of immunohistochemical and biochemical methods. Breast Cancer Res Treat 43:221-228, 1997
40. McCarty KSJ, Miller LS, Cox EB, et al: Estrogen receptor analyses: Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med 109:716-721, 1985
41. Pertschuk LP, Eisenberg KB, Carter AC, et al: Immunohistologic localization of estrogen receptors in breast cancer with monoclonal antibodies: Correlation with biochemistry and clinical endocrine response. Cancer 55:1513-1518, 1985
42. Ozzello L, DeRosa C, Habif DV, et al: Immunostaining of estrogen receptors in paraffin sections of breast cancers using anti-estrophilin monoclonal antibodies, in Ceriani RL (ed): Monoclonal Antibodies in Breast Cancer. Boston, MA, Martinus Nijhoff, 1985, pp 3-12
43. Jonat W, Maass H, Stegner HE: Immunohistochemical measurement of estrogen receptors in breast cancer tissue samples. Cancer Res 46:4296S-4298S, 1986 (suppl)
44. McClelland RA, Berger U, Miller LS, et al: Immunocytochemical assay for estrogen receptor: Relationship to outcome of therapy in patients with advanced breast cancer. Cancer Res 46:4241S-4243S, 1986 (Suppl)
45. Berger U, Mansi JL, Wilson P, et al: Detection of estrogen receptor in bone marrow from patients with metastatic breast cancer. J Clin Oncol 5:1779-1782, 1987
46. Burton GV, Flowers JL, Cox EB, et al: Estrogen receptor determination by monoclonal antibody in fine needle aspiration breast cancer cytologies: A marker of hormone response. Breast Cancer Res Treat 10:287-291, 1987
47. Coombes RC, Powles TJ, Berger U, et al: Prediction of endocrine response in breast cancer by immunocytochemical detection of oestrogen receptor in fine-needle aspirates. Lancet 2:701-703, 1987
48. De Lena M, Marzullo F, Simnone G, et al: Correlation between ERICA and DCC assay in hormone receptor assessment of human breast cancer. Oncology 45:308-312, 1988
49. Andersen J, Poulsen HS: Immunohistochemical analysis of estrogen receptors (ER) using formalin-fixed paraffin-embedded breast cancer tissue: Correlation with clinical endocrine response. J Steroid Biochem 30:337-339, 1988
50. Hawkins RA, Sangster K, Tesdale A, et al: The cytochemical detection of oestrogen receptors in fine needle aspirates of breast cancer: Correlation with biochemical assay and prediction of response to endocrine therapy. Br J Cancer 58:77-80, 1988
51. Gaskell DJ, Hawkins RA, Sangster K, et al: Relation between immunocytochemical estimation of oestrogen receptor in elderly patients with primary breast cancer and response to tamoxifen. Lancet 1:1044-1046, 1989
52. Andersen J, Poulsen HS: Immunohistochemical estrogen receptor determination in paraffin-embedded tissue: Prediction of response to hormonal treatment in advanced breast cancer. Cancer 64:1901-1908, 1989
53. Sklarew RJ, Bodmer SC, Pertschuk LP: Quantitative imaging of immunocytochemical (PAP) estrogen receptor staining patterns in breast cancer sections. Cytometry 11:359-378, 1990
54. McClelland RA, Finlay P, Walker KJ, et al: Automated quantitation of immunocytochemically localized estrogen receptors in human breast cancer. Cancer Res 50:3545-3550, 1990
55. Goulding H, Pinder S, Cannon P, et al: A new immunohistochemical antibody for the assessment of estrogen receptor status on routine formalin-fixed tissue samples. Hum Pathol 26:291-294, 1995
56. Pertschuk LP, Feldman JG, Kim YD, et al: Estrogen receptor immunocytochemistry in paraffin embedded tissues with ER1D5 predicts breast cancer endocrine response more accurately than H222Sp gamma in frozen sections or cytosol-based ligand-binding assays. Cancer 77:2514-2519, 1996
57. Barnes DM, Harris WH, Smith P, et al: Immunohistochemical determination of oestrogen receptor: Comparison of different methods of assessment of staining and correlation with clinical outcome of breast cancer patients. Br J Cancer 74:1445-1451, 1996